Member access

4-Traders Homepage  >  Shares  >  SINGAPORE EXCHANGE  >  Luye Pharma Group Ltd    LUYE   BMG5722Z1014

SummaryChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

LUYE PHRM : Exercise Of The Call Option By Luye Biotech (Singapore) Pte Ltd Under The Investment Agreement To Acquire All The Shares Held By Biomedical Sciences Investment Fund Pte Ltd In The Issued Share Capital Of A-Bio Pharma Pte Ltd

07/25/2011 | 06:35am US/Eastern
Recommend:
0

LUYE PHARMA GROUP LTD.

(INCORPORATED IN BERMUDA)

EXERCISE OF THE CALL OPTION BY LUYE BIOTECH (SINGAPORE) PTE LTD UNDER THE INVESTMENT AGREEMENT TO ACQUIRE ALL THE SHARES HELD BY BIOMEDICAL SCIENCES INVESTMENT FUND PTE LTD IN THE ISSUED SHARECAPITAL OF A-BIO PHARMA PTE LTD

Where capitalised terms are used in this announcement and not otherwise defined, such capitalised terms shall bear the same meanings as ascribed to them in the Company?s announcement dated

30 July 2010 in relation to the Strategic Investment in A-Bio Pharma Pte Ltd by Luye-Biotech

(Singapore) Pte Ltd.

The Board of Directors of Luye Pharma Group Ltd. (?Luye? or ?the Company?) is pleased to announce that Luye Biotech, a wholly-owned subsidiary of the Company, has exercised the Call Option under the Investment Agreement to acquire all of BMSIF?s shares comprising (i) one (1) ordinary share and (ii) 2,500,000 preference shares (Series B Preferred Shares) (collectively known as the ?Call Option Shares?) in A-Bio Pharma Pte Ltd (?A-Bio?) at a Option Consideration of S$2,750,000.

When the acquisition is completed, the Company will own 100% of the entire issued share capital of A-Bio through another wholly-owned subsidiary, Shandong Luye Pharmaceutical Co. Ltd.

The Option Consideration will funded by internal resources and is not expected to have any material impact on the net tangible assets per share and earnings per share of the Company for the current financial year ending 31 December 2011.

None of the Directors or controlling shareholders has any interest, directly or indirectly, in the transaction.

By Order of the Board

Liu Dianbo

Executive Chairman

Date: 25 July 2011

Recommend :
0
React to this article
Latest news on LUYE PHARMA GROUP LTD
2d ago LUYE PHARMA : gets registration certificate for oncology product
09/01 LUYE PHARMA : 5.00m shrs for HK$43.70m
08/28 LUYE PHARMA : to Take Stake in Beijing Jialin
08/27 LUYE PHARMA : buys stake in Beijing Jialin Pharm at Rmb3.7bn
08/22 LUYE PHARMA : Beijing Hanmi Team Up, Developing Cancer Drugs
08/22 Luye Pharma (02186) to develop drug with Korea's Hanmi
08/12 LUYE PHARMA : Citi starts Luye Pharma at HK$8.5
07/28 Citi to hire 100 bankers in Asia, eyes more business from smaller clients
07/09DJLuye, Tian Ge Stage Strong Debuts in Hong Kong
02/13 LUYE PHARMA GROUP LTD : 2013 China Chemical Pharmaceutical Industry Excellent Co..
Advertisement
Chart
Duration : Period :
Luye Pharma Group Ltd Technical Analysis Chart | LUYE | BMG5722Z1014 | 4-Traders
Income Statement Evolution
Luye Pharma Group Ltd : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF